Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Hong Kong ETF (EWH) vs Eli Lilly And Co (LLY) Price & Performance

iShares MSCI Hong Kong ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Hong Kong ETF vs Eli Lilly And Co — how do they compare? iShares MSCI Hong Kong ETF trades at $22.04, while Eli Lilly And Co trades at $1,168 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals.

EWHLLY
Sector
Broad Market / FactorHealth
52-Week High
$24.55$1.24K
52-Week Low
$20.15$625.65
Market Cap
$1.03T
Enterprise Value
$1.07T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Hong Kong ETF

EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 1.71% with a bullish technical signal from moving averages. The ETF tracks Hong Kong equities, showing recent momentum in Chinese technology stocks as highlighted in recent market coverage. Key resistance and support cluster around $22, while RSI readings suggest potential overbought conditions. The fund declared a $0.35 dividend payable in June 2026.

Outlook remains tied to Hong Kong market performance and Chinese economic factors. Positive catalysts include technology sector rallies and Hong Kong's growing wealth hub status, but risks involve regulatory scrutiny on Chinese brokerages and IPO performance concerns. Investor sentiment is cautiously optimistic amid regional market volatility.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.

Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Hong Kong ETF

EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.

Read more on EWH

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY